Last year, TrialSite published “A Familyman’s Battle Against the Forefront of the Capitalist Medicine: the Case of Errant Gene Therapeutics,” which depicted Patrick Girondi, an ex-commodity trader who grew up in Chicago’s tough southside in a rags to riches...
Bluebird Bio.
Category
EGT Wins Appeal Ruling Against Sloan-Kettering, Bluebird Bio; Cases Proceed Towards Trial
In a big legal step, on April 30, the New York Supreme Court upheld lawsuits by Errant Gene Therapeutics (EGT) against Sloan-Kettering (SKI) and Bluebird Bio. TrialSite News has been following this saga, with our latest prior update here. According to EGT’s press...
Novo Nordisk Enters into Agreement with Bluebird Bio, a Company Currently in Litigation with Errant Gene Therapeutics
Novo Nordisk and Bluebird Bio., previously known as Genetix and purchased by Third Rock Ventures, will collaborate to develop genome editing treatments for genetic diseases, citing specifically the bleeding disease hemophilia as a target disorder, noted Jonathan...